Response to: Investigating the neurobehavioral symptoms of neuronopathic Hunter syndrome

Response to: Investigating the neurobehavioral symptoms of neuronopathic Hunter syndrome

Bibliographic Details
Main Authors:	J.B. Eisengart, K.E. King, E. Shapiro, C.B. Whitley, J. Muenzer
Format:	Article
Language:	English
Published:	Elsevier 2020-03-01
Series:	Molecular Genetics and Metabolism Reports
Subjects:	Mucopolysaccharidosis II Hunter syndrome Neurobehavioral symptoms Behavioral decline Neuronopathic phenotype
Online Access:	http://www.sciencedirect.com/science/article/pii/S2214426920300161

Similar Items

Investigating the neurobehavioral symptoms of neuronopathic Hunter syndrome
by: Nathan Grant
Published: (2020-03-01)

Clinical characteristics and somatic burden of patients with mucopolysaccharidosis II with or without neurological involvement: An analysis from the Hunter Outcome Survey
by: Heather Lau, et al.
Published: (2023-12-01)

A post hoc analysis of Projected Retained Ability Scores (PRAS) for the longitudinal assessment of cognitive functioning in patients with neuronopathic mucopolysaccharidosis II receiving intrathecal idursulfase-IT
by: Karen S. Yee, et al.
Published: (2023-11-01)

Neuronopathic Types of Mucopolysaccharidoses: Pathogenesis and Emerging Treatments
by: L. A. Osipova, et al.
Published: (2015-11-01)

Clinical investigator perspectives on patient outcomes in children with neuronopathic mucopolysaccharidosis II during intrathecal idursulfase-IT treatment
by: Karen S. Yee, et al.
Published: (2024-04-01)

Caregiver experiences and observations of intrathecal idursulfase-IT treatment in a phase 2/3 trial in pediatric patients with neuronopathic mucopolysaccharidosis II
by: Karen S. Yee, et al.
Published: (2024-03-01)

Ten years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from a global patient registry
by: Joseph Muenzer, et al.
Published: (2017-05-01)

Treatment of Neuronopathic Mucopolysaccharidoses with Blood–Brain Barrier-Crossing Enzymes: Clinical Application of Receptor-Mediated Transcytosis
by: Hiroyuki Sonoda, et al.
Published: (2022-06-01)

Identification of 17 novel mutations in 40 Argentinean unrelated families with mucopolysaccharidosis type II (Hunter syndrome)
by: H. Amartino, et al.
Published: (2014-01-01)

Diagnosis and Management of Mucopolysaccharidosis Type II (Hunter Syndrome) in Poland
by: Zbigniew Żuber, et al.
Published: (2023-06-01)

A case of hunter syndrome and Alder-Reilly anomaly
by: Nour AlMozain, et al.
Published: (2017-01-01)

Neuroradiological Characteristics in Patients with Mucopolysaccharidosis Type II: A Systematic Review
by: Yancarlos Ramos-Villegas, et al.
Published: (2023-02-01)

Mucopolysaccharidosis type II (Hunter syndrome) in a boy from the Republic of Serbia: A case report
by: Tubić-Vukajlović Jovana M., et al.
Published: (2023-01-01)

Recovery of Vision following Enzyme Replacement Therapy in a Patient with Mucopolysaccharidosis Type II, Hunter Syndrome
by: Ryutaro Yamanishi, et al.
Published: (2019-06-01)

Posterior segment findings in Hunter Syndrome: Case report and review
by: Ishani P. Majmudar, et al.
Published: (2024-12-01)

Manifestaciones bucales de pacientes con mucopolisacaridosis// Oral manifestations in patients with mucopolysaccharidosis
by: Andrea Veronica Rios
Published: (2021-01-01)

Current Approaches to the Treatment of Hunter Syndrome
by: Ekaterina Yu. Zakharova, et al.
Published: (2018-10-01)

Beneath the floor: re-analysis of neurodevelopmental outcomes in untreated Hurler syndrome
by: Elsa G. Shapiro, et al.
Published: (2018-05-01)

Burden of caregivers of patients with neuronopathic and non-neuronopathic Gaucher disease in Japan: A survey-based study
by: Yuta Koto, et al.
Published: (2023-09-01)

Neuronopathic Gaucher disease: Beyond lysosomal dysfunction
by: Nohela B. Arévalo, et al.
Published: (2022-08-01)

Clinical Profile Among Brazilian Mucopolysaccharidosis type II Patients: Subgroup Analysis from the Hunter Outcome Survey
by: Dafne D G Horovitz, et al.
Published: (2023-09-01)

Typical imaging features in hunter’s syndrome
by: L De Cocker Jr, et al.
Published: (2010-03-01)

Management of Difficult Airway in a Patient with Mucopolysaccharidosis Type II
by: Damla Hanalioğlu, et al.
Published: (2019-08-01)

Mucopolysaccharidosis Type-II with Pathognomonic Skin Appearance: A Case with Pebbling Sign
by: Ayşe Hitay İnan, et al.
Published: (2021-06-01)

Enhanced osteoblastic differentiation of parietal bone in a novel murine model of mucopolysaccharidosis type II
by: Narutoshi Yamazaki, et al.
Published: (2023-12-01)

Clinical, Biochemical and Molecular Characteristics of Fifteen Patients with Mucopolysaccharidosis Type II in Western Turkey
by: Havva Yazıcı, et al.
Published: (2018-03-01)

Enzyme Replacement Therapy with Idursulfase in Patients with Mucopolysaccharidosis Type II: Literature Review
by: Nato D. Vashakmadze, et al.
Published: (2021-12-01)

A global neuronopathic gaucher disease registry (GARDIAN): a patient-led initiative
by: Tanya Collin-Histed, et al.
Published: (2023-07-01)

Analysis of caregiver perspectives on patients with mucopolysaccharidosis II treated with pabinafusp alfa: results of qualitative interviews in Japan
by: Kimitoshi Nakamura, et al.
Published: (2024-03-01)

Neurobehavioral Deficits and Parkinsonism in Occupations with Manganese Exposure: A Review of Methodological Issues in the Epidemiological Literature
by: Robert M. Park
Published: (2013-09-01)

Neurobehavioral Effects of Low-Dose Chronic Exposure to Insecticides: A Review
by: Laura Maria Antonangeli, et al.
Published: (2023-02-01)

Validation and Implementation of a Highly Sensitive and Efficient Newborn Screening Assay for Mucopolysaccharidosis Type II
by: Heather Bilyeu, et al.
Published: (2020-10-01)

Efficacy of early haematopoietic stem cell transplantation versus enzyme replacement therapy on neurological progression in severe Hunter syndrome: Case report of siblings and literature review
by: Srividya Sreekantam, et al.
Published: (2022-09-01)

Neurobehavioral Comorbidities of Active Epilepsy
by: J Gordon Millichap, et al.
Published: (2014-07-01)

Editorial: Neuronopathic lysosomal storage diseases - specific neuronal characteristics and therapeutic approaches
by: Stefanie Flunkert, et al.
Published: (2022-11-01)

The neurobehavioral phenotype in mucopolysaccharidosis Type IIIB: An exploratory study
by: E. Shapiro, et al.
Published: (2016-03-01)

Intracerebroventricular Enzyme Replacement Therapy in Patients with Neuropathic Form of Mucopolysaccharidosis Type II: to Help Practicing Physician
by: Nataliya V. Zhurkova, et al.
Published: (2024-09-01)

Producción de anticuerpos policlonales IgG contra la proteina iduronato-2-sulfato sulfatasa y desarrollo de un sistema de detección para IDS humana recombinante.
by: Olga Peña, et al.
Published: (2005-06-01)

Potential neurobehavioral toxicity of sulfur in mice
by: Firas S. Hassan
Published: (2023-07-01)

Neurobehavioral Risk Factors in Schizophrenia
by: J Gordon Millichap
Published: (1999-08-01)